AASLD

AASLD
November 04-08, 2022
Washington DC USA

American Association for the Study of Liver Diseases.

Explore more information for Gilead Liver Diseases therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (7)

    Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis delta: an integrated safety analysis of 48-week data

    • Author(s): Asselah, T
    • bulevirtide
    • Liver Diseases

    Efficacy of Bulevirtide as Monotherapy for Chronic Hepatitis D (CHD): Week-48 Results From an Integrated Analysis

    • Author(s): Lampertico, P
    • bulevirtide
    • Liver Diseases

    Combination Therapy with Cilofexor and Firsocostat Improves Plasma Fibrosis Biomarkers in Patients with Advanced Fibrosis Due to Non-Alcoholic Steatohepatitis

    • Author(s): Kowdley, K
    • cilofexor/firsocostat/semaglutide
    • Liver Diseases

    Curing HCV with Direct-Acting Antiviral (DAA) Treatment: Adherence And Rapid Onset Of HCV RNA Undetectability After 4 Weeks of Treatment with Sofosbuvir/Velpatasvir

    • Author(s): Flamm, S
    • epclusa
    • Liver Diseases

    No Detected Resistance to Tenofovir Alafenamide (TAF) Treatment in Children and Adolescents with Chronic Hepatitis B (CHB): Results From Week 24 Primary Endpoint Analysis

    • Author(s): Schwarz, K
    • vemlidy
    • Liver Diseases

    Bulevirtide improves health related quality life measured by EQ-5D VAS in patients with chronic hepatitis delta: An exploratory analysis of a phase 3 trial at 48 weeks

    • Author(s): Buti, M
    • bulevirtide
    • Liver Diseases

    Safety and efficacy at 1 year in children and adolescents with chronic hepatitis B (CHB) receiving tenofovir alafenamide (TAF)

    • Author(s): Schwarz, K
    • vemlidy
    • Liver Diseases